Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer
Y Chen, Z Chen, R Chen, C Fang, C Zhang, M Ji… - Future …, 2022 - Taylor & Francis
The rapid development of molecular targeted therapy brings hope to patients with advanced
non-small-cell lung cancer (NSCLC). However, drug resistance inevitably occurs during …
non-small-cell lung cancer (NSCLC). However, drug resistance inevitably occurs during …
[HTML][HTML] Effectiveness of PD1/PD-L1 combined with anti-angiogenic drugs in patients with advanced nonsmall cell lung cancer: A systematic review and meta-analysis
X Duan, X Liu, R Chen, Y Pu - Journal of Research in Medical …, 2024 - journals.lww.com
Background: Protein-1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) therapy have
become an important treatment approach for patients with advanced nonsmall cell lung …
become an important treatment approach for patients with advanced nonsmall cell lung …
Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients
S Yuan, L Peng, Y Liu, BG Till, X Yan, J Zhang… - Cancer Immunology …, 2023 - Springer
Background Anti-angiogenic drugs increase anti-tumor efficacy of immune checkpoint
inhibitors (ICIs). However, the optimal dose of anti-angiogenic drugs remains unclear …
inhibitors (ICIs). However, the optimal dose of anti-angiogenic drugs remains unclear …
[HTML][HTML] Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study
T Chu, W Zhang, B Zhang, R Zhong… - Translational Lung …, 2022 - ncbi.nlm.nih.gov
Background The evidence of combined therapies of multi-target agents in first-line treatment
of advanced non-small cell lung cancer (NSCLC) was limited. This study aimed to evaluate …
of advanced non-small cell lung cancer (NSCLC) was limited. This study aimed to evaluate …
Efficacy and safety of anlotinib-containing regimens in advanced non-small cell lung cancer: a real-world study
L Sun, Q Zhao, Y Wang, Y Wang, M Zheng… - … Journal of General …, 2023 - Taylor & Francis
Purpose Anlotinib is widely used in the clinical treatment of non-small cell lung cancer
(NSCLC), alone or in combination with other anticancer drugs. The aim of this study was to …
(NSCLC), alone or in combination with other anticancer drugs. The aim of this study was to …
[HTML][HTML] Anlotinib hydrochloride and PD-1 blockade as a salvage second-line treatment in patients with progress of local advanced non-small cell lung cancer in half a …
C Yu, L Jiang, D Yang, X Dong, R Yu… - OncoTargets and …, 2022 - ncbi.nlm.nih.gov
Purpose As for local advanced non-small cell lung cancer (NSCLC), synchronous
radiotherapy and chemotherapy is the standard treatment mode. But for patients with …
radiotherapy and chemotherapy is the standard treatment mode. But for patients with …
Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: a systematic review …
K Matsumoto, T Shiroyama, T Kuge, K Miyake… - Lung Cancer, 2021 - Elsevier
Objective Several studies have demonstrated that anti-angiogenic agents (AAs) have the
ability to regulate immune-related cells in the tumor microenvironment and may affect the …
ability to regulate immune-related cells in the tumor microenvironment and may affect the …
[HTML][HTML] The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report
W Deng, J Chen, XY Deng - Frontiers in Immunology, 2024 - frontiersin.org
Background Extensive-stage small-cell lung cancer (ES-SCLC) is highly malignant, with
early metastasis and high recurrence. Since therapeutic options are limited, ES-SCLC has a …
early metastasis and high recurrence. Since therapeutic options are limited, ES-SCLC has a …
[HTML][HTML] The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center …
X Yin, X Liu, F Ren, X Meng - Cancer Immunology, Immunotherapy, 2024 - Springer
Background Effective treatment after EGFR-TKI resistance is of great clinical concern. We
aimed to investigate the efficacy and safety of anlotinib in combination with an anti-PD-1/PD …
aimed to investigate the efficacy and safety of anlotinib in combination with an anti-PD-1/PD …
[HTML][HTML] Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized …
C Zhang, T Chu, Q Wang, Y Cheng… - Cancer Biology & …, 2024 - cancerbiomed.org
Objective: The possible enhancing effect of anlotinib on programmed death receptor ligand
(PD-L1) antibody and the efficacy-predicting power of PD-L1 in micro-conduit endothelium …
(PD-L1) antibody and the efficacy-predicting power of PD-L1 in micro-conduit endothelium …